Роберто Пили

19.4k citations

289 papers · 13.0k indexed · 3 hit papers · h-index 59

Impact in

Cancer Research top 0.2%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
Oncology top 0.5%

Papers in

Pulmonary and Respiratory Medicine 140
- Renal cell carcinoma treatment 69
- Prostate Cancer Treatment and Research 63
Cancer Research 54
- Cancer Genomics and Diagnostics 22

Co-authors: Michael A. Carducci David Z. Qian Hans J. Hammers Antonino Passaniti Leigh Ellis Li Shen Henk M.W. Verheul Peter Atadja
Journals: Journal of Clinical Oncology (61 papers)Clinical Cancer Research (21 papers)Cancer Research (19 papers)Molecular Cancer Therapeutics (8 papers)Oncotarget (8 papers)
Partner nations: United States Italy Canada

In The Last Decade

Роберто Пили

280 papers receiving 12.8k citations

Hit Papers

align trajectories log scale

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma 2009 · 1.7k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 Journal of Clinical Oncology
2008 Proceedings of the National Academy of Sciences
1992 PubMed

Peers

Countries citing papers authored by Роберто Пили

Since Specialization

Citations

This map shows the geographic impact of Роберто Пили's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Роберто Пили with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Роберто Пили more than expected).

Fields of papers citing papers by Роберто Пили

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Роберто Пили. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Роберто Пили. The network helps show where Роберто Пили may publish in the future.

Co-authors

The 25 scholars most cited alongside Роберто Пили, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Роберто Пили Line = papers co-authored together Роберто Пили links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The integration of big data analytics in examining the effects of mental illness screening on mortality and burden of illness among patients with cancer. Journal of Clinical Oncology ·Minu P. Mohan, Joel B. Epstein, Naheed Alam, Shaniza Haniff, Роберто Пили, Poolakkad S. Satheeshkumar	2024	0
2	Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer Cancer Research ·Elena Beketova, Shuyi Fang, Jake L. Owens, Sheng Liu, Xufeng Chen, Qingfu Zhang, Andrew M. Asberry, Xuehong Deng, Jonathan Malola, Jiaoti Huang, Chenglong Li, Роберто Пили, Bennett D. Elzey, Timothy L. Ratliff, Jun Wan, Chang‐Deng Hu	2020	28
3	Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy Nature Communications ·Hayley C. Affronti, Aryn M. Rowsam, Anthony J. Pellerite, Spencer R. Rosario, Mark D. Long, Justine J. Jacobi, Anna Bianchi, Christoph S. Boerlin, Bryan M. Gillard, Ellen Karasik, Barbara A. Foster, Michael T. Moser, John H. Wilton, Kristopher Attwood, Mikhail A. Nikiforov, Gissou Azabdaftari, Роберто Пили, James G. Phillips, Robert A. Casero, Dominic J. Smiraglia	2020	46
4	Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma Molecular Cancer Therapeutics ·May Elbanna, Ashley Orillion, Nur P. Damayanti, Remi Adelaiye‐Ogala, Li Shen, Kiersten Marie Miles, Sreenivasulu Chintala, Eric Ciamporcero, Swathi Ramakrishnan, Sheng‐Yu Ku, Karen Rex, Sean Caenepeel, Angela Coxon, Роберто Пили	2019	10
5	Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer Molecular Cancer Therapeutics ·Melissa L. Fishel, Hanyu Xia, Jack McGeown, David W. McIlwain, May Elbanna, Ariel A. Craft, Hristos Z. Kaimakliotis, George E. Sandusky, Chi Zhang, Роберто Пили, Mark R. Kelley, Travis J. Jerde	2019	31
6	Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas Clinical Cancer Research ·John A. Thompson, Robert J. Motzer, Ana M. Molina, Toni K. Choueiri, Elisabeth I. Heath, Bruce G. Redman, Randeep Sangha, D. Scott Ernst, Роберто Пили, Stella K. Kim, Leonard Reyno, Aya Wiseman, Fabio Trave, Banmeet S. Anand, Karen Morrison, Fernando Doñate, Christian Kollmannsberger	2018	48
7	Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma Cancer Research ·Remi Adelaiye‐Ogala, Nur P. Damayanti, Ashley Orillion, Sreevani Arisa, Sreenivasulu Chintala, Mark Titus, Chinghai Kao, Роберто Пили	2018	29
8	Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy Clinical Cancer Research ·Ashley Orillion, Nur P. Damayanti, Li Shen, Remi Adelaiye‐Ogala, Hayley C. Affronti, May Elbanna, Sreenivasulu Chintala, Michael J. Ciesielski, Luigi Fontana, Chinghai Kao, Bennett D. Elzey, Timothy L. Ratliff, David E. Nelson, Dominic J. Smiraglia, Scott I. Abrams, Роберто Пили	2018	85
9	Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma Clinical Cancer Research ·Nur P. Damayanti, Justin A. Budka, Heba Khella, Mary W. Ferris, Sheng‐Yu Ku, Eric Kauffman, Anthony C. Wood, Khunsha Ahmed, Venkata Nithinsai Chintala, Remi Adelaiye‐Ogala, May Elbanna, Ashley Orillion, Sreenivasulu Chintala, Chinghai Kao, W. Marston Linehan, George M. Yousef, Peter C. Hollenhorst, Роберто Пили	2018	61
10	Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma Clinical Cancer Research ·Ashley Orillion, Ayumi Hashimoto, Nur P. Damayanti, Li Shen, Remi Adelaiye‐Ogala, Sreevani Arisa, Sreenivasulu Chintala, Peter Ordentlich, Chingai Kao, Bennett D. Elzey, Dmitry I. Gabrilovich, Роберто Пили	2017	291
11	Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) Clinical Cancer Research ·Роберто Пили, David I. Quinn, Hans J. Hammers, Paul Monk, Saby George, Tanya B. Dorff, Thomas Olencki, Li Shen, Ashley Orillion, Dominick Lamonica, Roberto S. Fragomeni, Zsolt Szabó, Alan D. Hutson, Adrienne Groman, Susan M. Perkins, Richard Piekarz, Michael A. Carducci	2017	76
12	Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer Clinical Cancer Research ·Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig, Franklin Chu, Роберто Пили, Joseph J. Stephenson, Nicholas J. Vogelzang, Alan J. Koletsky, Luke T. Nordquist, William J. Edenfield, Khalid Mamlouk, Karen J. Ferrante, Mary-Ellen Taplin	2015	64
13	Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications Molecular Cancer Therapeutics ·Remi Adelaiye‐Ogala, Eric Ciamporcero, Kiersten Marie Miles, Paula Sotomayor, Jonathan Bard, Maria Tsompana, Dylan Conroy, Li Shen, Swathi Ramakrishnan, Sheng‐Yu Ku, Ashley Orillion, Joshua Prey, Gerald J. Fetterly, Michael Buck, Sreenivasulu Chintala, Georg A. Bjarnason, Роберто Пили	2014	56
14	Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models Cancer Immunology Research ·Li Shen, Anette Sundstedt, Michael J. Ciesielski, Kiersten Marie Miles, Mona Celander, Remi Adelaiye‐Ogala, Ashley Orillion, Eric Ciamporcero, Swathi Ramakrishnan, Leigh Ellis, Robert A. Fenstermaker, Scott I. Abrams, Helena Eriksson, Tomas Leanderson, Anders Olsson, Роберто Пили	2014	74
15	Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Andrew J. Armstrong, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, Vasily J. Assikis, Jonathan Polikoff, J.‐E. Damber, Laurence Belkoff, Örjan Nordle, G. Forsberg, Michael A. Carducci, Роберто Пили	2013	46
16	Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks Clinical Cancer Research ·John M.L. Ebos, Роберто Пили	2012	10
17	Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance Clinical Cancer Research ·Kristy J. Gotink, Henk J. Broxterman, Mariëtte Labots, Richard R. de Haas, Henk Dekker, Richard J. Honeywell, Michelle A. Rudek, Laurens V. Beerepoot, René J. P. Musters, Gerrit Jansen, Arjan W. Griffioen, Yehuda G. Assaraf, Роберто Пили, Godefridus J. Peters, Henk M.W. Verheul	2011	290
18	Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer Journal of Clinical Oncology ·Роберто Пили, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, Vasileios J. Assikis, Anders Björk, Örjan Nordle, G. Forsberg, Michael A. Carducci, Andrew J. Armstrong	2011	161
19	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Journal of Clinical Oncology ·Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin Hit paper breakdown →	2009	1711
20	Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer Journal of Clinical Oncology ·Michael A. Carducci, Luna Musib, Merrill S. Kies, Роберто Пили, Mylene T. Truong, Julie R. Brahmer, Patricia E. Cole, Rana Sullivan, Jeanne R. Riddle, Jill Schmidt, Nathan Enas, Vikram Sinha, Donald Thornton, Roy S. Herbst	2006	150

About Роберто Пили

Роберто Пили is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Molecular Biology and Neuropsychology and Physiological Psychology, having authored 289 papers that have together received 13.0k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (69 papers), Prostate Cancer Treatment and Research (63 papers), Histone Deacetylase Inhibitors Research (53 papers), Epigenetics and DNA Methylation (30 papers), Cancer Genomics and Diagnostics (22 papers), Renal and related cancers (21 papers), Angiogenesis and VEGF in Cancer (19 papers) and Protein Degradation and Inhibitors (19 papers). The work is most often cited by research in Cancer Research (3.0k citations), Oncology (3.8k citations), Pulmonary and Respiratory Medicine (4.2k citations), Molecular Biology (7.8k citations) and Immunology (1.3k citations). Роберто Пили has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Michael A. Carducci, David Z. Qian, Hans J. Hammers, Antonino Passaniti, Leigh Ellis, Li Shen, Henk M.W. Verheul, Peter Atadja, George Wilding and Robert J. Motzer. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer Research, Molecular Cancer Therapeutics and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact